Medtronic CFO: No shift away from GPOs

Medtronic CFO Gary Ellis has explained to investors that the medical device maker isn't making a strategic shift away from group purchasing organizations, despite the recent cancellation of several contracts with Premier and Novation. "There's a lot of speculation around here that a strategic change is going on," Ellis told analysts at the Barclay's Capital Investors Conference in Miami. "That is not the case." News

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.